Contributors
STE ´ PHANE AUDEBERT • Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes,
CRCM, Marseille Prote ´omique, Marseille, France
ERIC BAILLY • Centre de Recherche en Cance ´rologie de Marseille (CRCM), Aix-Marseille
Universite ´, Inserm, CNRS, Institut Paoli-Calmettes, Marseille, France
JAVIER R. BALBOA • Department of Drug Design and Pharmacology, Center for
Biopharmaceuticals, University of Copenhagen, Copenhagen, Denmark; Novo Nordisk A/
S, Research Chemistry 3, Ma ˚ løv, Denmark
ELSA BAZELLIE ` RES • Aix Marseille Universite ´, CNRS, IBDM–UMR7288, Turing Centre for
Living Systems, Marseille, France
GORAN BICH • (Equipe labelise ´e Ligue, 2015) Institut de Ge ´ne ´tique et de Biologie Mole ´culaire
et Cellulaire (IGBMC), INSERM U1258/CNRS UMR 7104/Universite ´ de Strasbourg,
Illkirch, France
JEAN-PAUL BORG • Centre de Recherche en Cance ´rologie de Marseille, Aix-Marseille
University, Inserm, CNRS, Institut Paoli-Calmettes, Marseille, France; Institut
Universitaire de France (IUF), Paris, France
SE ´ BASTIEN BRU ˆ LE ´ • Institut Pasteur, Plate-forme de Biophysique Mole ´culaire, CNRS UMR
3528, Paris, France
CE ´ LIA CAILLET-SAGUY • Institut Pasteur, Unite ´ Re ´cepteurs-Canaux, CNRS UMR 3571,
Paris, France
LUC CAMOIN • Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM,
Marseille Prote ´omique, Marseille, France
CARLOS CASTAN ˜ O-RODRIGUEZ • Department of Molecular and Cell Biology, Centro Nacional
de Biotecnologı ´a (CNB-CSIC), Madrid, Spain
MONICA CASTRO-CRUZ • Centre de Recherche en Cancerologie de Marseille (CRCM), Equipe
Zimmermann labellise ´e Ligue 2018 – 2019, Aix-Marseille Universite ´, Inserm, CNRS,
Institut Paoli-Calmettes, Marseille, France; Department of Human Genetics, K. U.
Leuven, Leuven, Belgium
LIONEL CHIRON • CASC4DE, Strasbourg, France
LOUISE S. CLEMMENSEN • Department of Drug Design and Pharmacology, Center for
Biopharmaceuticals, University of Copenhagen, Copenhagen, Denmark
AVAIS M. DAULAT • Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes,
CRCM, Equipe labellise ´e Ligue ‘Cell polarity, cell signaling and cancer’, Marseille, France
ANTONIO LUIS EGEA-JIMENEZ • Centre de Recherche en Cance ´rologie de Marseille (CRCM),
Equipe Zimmermann labellise ´e Ligue 2018, Aix-Marseille Universite ´, Inserm, CNRS and
Institut Paoli-Calmettes, Marseille, France
LUIS ENJUANES • Department of Molecular and Cell Biology, Centro Nacional de
Biotecnologı ´a (CNB-CSIC), Madrid, Spain
DOMINIK J. ESSIG • Department of Drug Design and Pharmacology, Center for
Biopharmaceuticals, University of Copenhagen, Copenhagen, Denmark; Novo Nordisk A/
S, Research Chemistry 3, Ma ˚ løv, Denmark
ERNESTO J. FUENTES • Department of Biochemistry, University of Iowa, Iowa City, IA, USA;
Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA
ix
STE ´ PHANE AUDEBERT • Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes,
CRCM, Marseille Prote ´omique, Marseille, France
ERIC BAILLY • Centre de Recherche en Cance ´rologie de Marseille (CRCM), Aix-Marseille
Universite ´, Inserm, CNRS, Institut Paoli-Calmettes, Marseille, France
JAVIER R. BALBOA • Department of Drug Design and Pharmacology, Center for
Biopharmaceuticals, University of Copenhagen, Copenhagen, Denmark; Novo Nordisk A/
S, Research Chemistry 3, Ma ˚ løv, Denmark
ELSA BAZELLIE ` RES • Aix Marseille Universite ´, CNRS, IBDM–UMR7288, Turing Centre for
Living Systems, Marseille, France
GORAN BICH • (Equipe labelise ´e Ligue, 2015) Institut de Ge ´ne ´tique et de Biologie Mole ´culaire
et Cellulaire (IGBMC), INSERM U1258/CNRS UMR 7104/Universite ´ de Strasbourg,
Illkirch, France
JEAN-PAUL BORG • Centre de Recherche en Cance ´rologie de Marseille, Aix-Marseille
University, Inserm, CNRS, Institut Paoli-Calmettes, Marseille, France; Institut
Universitaire de France (IUF), Paris, France
SE ´ BASTIEN BRU ˆ LE ´ • Institut Pasteur, Plate-forme de Biophysique Mole ´culaire, CNRS UMR
3528, Paris, France
CE ´ LIA CAILLET-SAGUY • Institut Pasteur, Unite ´ Re ´cepteurs-Canaux, CNRS UMR 3571,
Paris, France
LUC CAMOIN • Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM,
Marseille Prote ´omique, Marseille, France
CARLOS CASTAN ˜ O-RODRIGUEZ • Department of Molecular and Cell Biology, Centro Nacional
de Biotecnologı ´a (CNB-CSIC), Madrid, Spain
MONICA CASTRO-CRUZ • Centre de Recherche en Cancerologie de Marseille (CRCM), Equipe
Zimmermann labellise ´e Ligue 2018 – 2019, Aix-Marseille Universite ´, Inserm, CNRS,
Institut Paoli-Calmettes, Marseille, France; Department of Human Genetics, K. U.
Leuven, Leuven, Belgium
LIONEL CHIRON • CASC4DE, Strasbourg, France
LOUISE S. CLEMMENSEN • Department of Drug Design and Pharmacology, Center for
Biopharmaceuticals, University of Copenhagen, Copenhagen, Denmark
AVAIS M. DAULAT • Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes,
CRCM, Equipe labellise ´e Ligue ‘Cell polarity, cell signaling and cancer’, Marseille, France
ANTONIO LUIS EGEA-JIMENEZ • Centre de Recherche en Cance ´rologie de Marseille (CRCM),
Equipe Zimmermann labellise ´e Ligue 2018, Aix-Marseille Universite ´, Inserm, CNRS and
Institut Paoli-Calmettes, Marseille, France
LUIS ENJUANES • Department of Molecular and Cell Biology, Centro Nacional de
Biotecnologı ´a (CNB-CSIC), Madrid, Spain
DOMINIK J. ESSIG • Department of Drug Design and Pharmacology, Center for
Biopharmaceuticals, University of Copenhagen, Copenhagen, Denmark; Novo Nordisk A/
S, Research Chemistry 3, Ma ˚ løv, Denmark
ERNESTO J. FUENTES • Department of Biochemistry, University of Iowa, Iowa City, IA, USA;
Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA
ix